Uber is the cleanest example I've found of the question value investors actually wrestle with: what do you do when a genuinely great business is trading at a merely *fair* price? Quick context for the setup. Bill Ackman's Pershing Square …
I’ve been looking at Zoetis after the recent selloff, and I think it is an interesting value setup. **The simple question:** Is Zoetis facing a structural impairment in companion animal demand and pricing power, or is the market overreacting to …
Every day i see some posts to buy microsoft because its cheap and has value. The truth is that im looking at most companies trying to figure out through ai to substitute all tools and make them as each CEO …
This post is kind of an educational post. A lot of people are currently talking about WEN and JACK. I want to give you some advice on what to look for in such a turnaround setup. Normally, if you want …
I am looking at Humana as a potential short. The stock is trading way outside of its historical trailing AND forward earnings even looking into 2027. In fact if you want to be bullish and see HUM putting up 17 …
**The Technical Bottleneck** Running next-generation Post-Quantum Cryptography (PQC) lattice math on classical silicon architectures triggers crippling network latency and severe data packet fragmentation across modern transport networks. Legacy Arithmetic Logic Units (ALUs) lack the specialized hardware-level engines required to efficiently …
The future of marketing is --> co-created, omni channel & personalized. And we are in the midst of this changing industry. When you interact across platforms, you leave traces of data!. Braze can leverage these cross channel interactions; create a …
Hi again r/ValueInvesting, for those who haven't seen my posts before: I'm the GM of the stock research side at Obermatt, a Swiss investment research firm. We rank stocks across 60+ markets on four factors (Value, Growth, Safety, Sentiment) relative …
HubSpot ( HUBS ) is a marketing software as a service platform - competing with SalesForce ( CRM ). HUBS is down 53% YTD. Revenue up 23% YOY (5 Y CAGR 28%) and operating income up from -23M to +29M …
TL;DR: Collegium ($COLL) sells patent-protected extended-release drugs for pain and ADHD. Asset-light, 61% gross margins, ~$290M owner earnings, revenue compounding ~20% for five years. Including ~$488M of net debt, the whole enterprise trades around 5.6x owner earnings. I think the …